Skip to main content
. 2021 Jul 6;36(1):109312. doi: 10.1016/j.celrep.2021.109312

Figure 2.

Figure 2

Secretomes of Salmonella-treated canine primary tumor cells prime an antitumor response in dogs affected by osteosarcoma and high-grade sarcoma

(A) Clinical trial scheme for dog patients with OSA and high-grade SA.

(B and C) Kaplan-Meier of metastasis free (B) and survival curve of (C) patients with OSA treated with carboplatin alone (black) or in combination with Vax (green).

(D and F) Tumor-specific IgG in dog sera shown as frequency of IgG-opsonized tumor cells.

(E and G) ELISA quantification of IFN-γ released by dog patient PBMCs upon stimulation with secretome from untreated (ut) or Salmonella-infected (Vax) SA/OSA cells.

Immunomonitoring experiments were performed once (D and F) or more (n = 2–3; C and E); each condition was tested at least in triplicate. Data are represented as mean ± SEM using a scatter dot plot. Statistical analysis was evaluated using log-rank Mantel-Cox (B), two-way ANOVA Tukey’s multiple comparison (C and E), and two-sided Mann-Whitney test (D and F). ∗p < 0.05,∗∗p < 0.01,∗∗∗p < 0.001,∗∗∗∗p < 0.0001. See also Figure S3.